Midazolam With Meperidine and Dexmedetomidine vs. Midazolam With Meperidine and Propofol for Sedation During ERCP

PHASE4CompletedINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

January 30, 2017

Conditions
Complication
Interventions
DRUG

Midazolam®

midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)

DRUG

"Meperidine (pethidine®)"

Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).

DRUG

Propofol®

Repeated doses of 10-20 mg propofol are titrated to achieve the target level of sedation.

DRUG

Dexmedetomidine (Precedex®)

Dexmedetomidine (1μg/kg/h, Precedex; Hospira, Seoul, Republic of Korea) or the same volume of normal saline were administered in the MMD and midazolam-meperidine group

Trial Locations (1)

330-715

Dankook University College of Medicine, Cheonan

All Listed Sponsors
lead

Dankook University

OTHER

NCT02475824 - Midazolam With Meperidine and Dexmedetomidine vs. Midazolam With Meperidine and Propofol for Sedation During ERCP | Biotech Hunter | Biotech Hunter